{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103071","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.205028+00:00","generated_at":"2026-05-17T20:58:19.720768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Terns Q2 net loss $24.1M; TERN-701 CML data and TERN-601 obesity data expected by year-end 2025","bullets":["Net loss $24.1M for Q2 2025 vs $22.7M in Q2 2024; R&D expenses $20.4M.","Cash, equivalents and securities $315.4M as of June 30, 2025; runway into 2028.","Phase 1 CARDINAL trial of TERN-701 in CML: efficacy/safety with 6-month MMR rates expected in 4Q25.","Phase 2 FALCON trial of TERN-601 in obesity completed enrollment; 12-week top-line data expected early 4Q25.","Company focusing on advancing TERN-701 in oncology; seeking partners for metabolic assets (TERN-800, TERN-501)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103071","json":"https://secwatch.observer/filing/0000950170-25-103071.json","markdown":"https://secwatch.observer/filing/0000950170-25-103071.md","text":"https://secwatch.observer/filing/0000950170-25-103071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025103071/0000950170-25-103071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025103071/tern-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:58:19.720768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}